About
About

We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
About Us

Leadership

Board of Directors

PCA Regenerative Medicine Advisory Board

Remyelination Advisory Board
Our Science
Our Science

Our PCA approach may represent a transformative step in the evolution of regenerative medicine, reducing complexity by temporarily reactivate progenitor cells already located at the tissue target site – and pre-programmed to make specific cell types.
PCA Approach

Therapeutic Discovery Process

Publications
Pipeline & Programs
Pipeline & Programs

Naturally repairing or reversing damage caused by degenerative disease
Pipeline

Multiple Sclerosis Program

Strategic Partnerships
Investors & Media
Investors & Media
Overview

Corporate Governance

Press Releases

Events & Presentations

Stock Information

Analyst Coverage

SEC Filings

Annual Reports and Proxy Statements

Investor FAQ

Investor & Media Contacts

SEC Filings

SEC Filings

Filing date	Description	Form	Filing Group	View
Sep 01, 2023	Pre-effective amendment to an S-4 filing	S-4/A	Registration Statements	0001193125-23-226463.pdf 0001193125-23-226463.rtf 0001193125-23-226463.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Sep 21, 2023	Pre-effective amendment to an S-4 filing	S-4/A	Registration Statements	0001193125-23-238780.pdf 0001193125-23-238780.rtf 0001193125-23-238780.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Sep 28, 2023	Pre-effective amendment to an S-4 filing	S-4/A	Registration Statements	0001193125-23-244637.pdf 0001193125-23-244637.rtf 0001193125-23-244637.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Nov 18, 2019	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-19-043670.pdf 0001564590-19-043670.rtf 0001564590-19-043670.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
May 14, 2020	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-20-025273.pdf 0001564590-20-025273.rtf 0001564590-20-025273.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
Aug 12, 2020	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-20-039488.pdf 0001564590-20-039488.rtf 0001564590-20-039488.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
Nov 16, 2020	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-20-054017.pdf 0001564590-20-054017.rtf 0001564590-20-054017.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
May 13, 2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-21-027221.pdf 0001564590-21-027221.rtf 0001564590-21-027221.xls EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
Aug 12, 2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0001564590-21-043699.pdf 0001564590-21-043699.rtf 0001564590-21-043699.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Nov 15, 2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	Quarterly Filings	0000950170-21-004466.pdf 0000950170-21-004466.rtf 0000950170-21-004466.xls EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT View HTML

Data provided by Kaleidoscope.